Program
abrysvo
Also written as “RSVpreF”, “RSVpreF Vaccine” and “RSVpreF (Regimen A)”.
Its studies are mostly in Respiratory Tract Infections · Respiratory Syncytial Virus Infections · COVID-19 · Influenza, Human, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 177 open or running | phase 3since Jun 3, 2020 | Jun 3, 2020 | Jan 18, 2027phase 3 · NCT05035212 |
| Hvivo | 10 open or running | phase 2since Feb 12, 2021 | Feb 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jun 3, 2020.
- Aug 20, 2021Phase 3 study in Lower Respiratory Tract IllnessPfizer · NCT05035212 · 38,861 enrolled · United States, Argentina, Canada and more
- Oct 14, 2021Phase 3 study in RSVPfizer · NCT05096208 · 1,028 enrolled · United States
- Mar 3, 2023Phase 1 study in Influenza, HumanPfizer · NCT05788237 · 508 enrolled · Argentina
- Apr 24, 2023Phase 3 study in RESPIRATORY SYNCYTIAL VIRUS (RSV)Pfizer · NCT05842967 · 885 enrolled · United States
- May 31, 2023Phase 2 study in COVID-19Pfizer · NCT05886777 · 1,142 enrolled · United States
- Jun 2, 2023Phase 1 study in Respiratory Tract InfectionsPfizer · NCT05900154 · 128 enrolled · United States
- Mar 8, 2024Phase 3 study in Respiratory Tract InfectionsPfizer · NCT06325657 · 681 enrolled · South Africa
- Sep 9, 2024Phase 3 study in Respiratory Tract InfectionsPfizer · NCT06593587 · 378 enrolled · South Korea
- Mar 4, 20252 phase 3 studiesPfizer · NCT06866405, NCT06890416
- Apr 15, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07543380 · 130 enrolled · Japan
- Jun 11, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07653100 · 540 planned · India
- Aug 12, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07768345 · 440 planned · United States
- Sep 8, 20262 phase 3 studiesPfizer · NCT07819097, NCT07839871
- Oct 14, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07885956 · 750 planned
Ahead
- Jan 18, 2027Primary completion: phase 3 study in Lower Respiratory Tract IllnessPfizer · NCT05035212
- Jan 25, 2027Primary completion: phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07653100
- May 16, 2027Primary completion: phase 3 study in AdultPfizer · NCT07819097
- Feb 2, 2028Primary completion: phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07768345
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07885956Respiratory Syncytial Virus (RSV) | 3 | Not yet recruiting | Pfizer | Feb 7, 2029 | 750 |
| NCT07839871Respiratory Syncytial Virus (RSV) · United States, Japan, Poland and more | 3 | Recruiting | Pfizer | Mar 30, 2031 | 920 |
| NCT07819097Adult · United States, China | 3 | Recruiting | Pfizer | May 16, 2027 | 600 |
| NCT07768345Respiratory Syncytial Virus (RSV) · United States | 3 | Recruiting | Pfizer | Feb 2, 2028 | 440 |
| NCT07653100Respiratory Syncytial Virus (RSV) · India | 3 | Recruiting | Pfizer | Jan 25, 2027 | 540 |
| NCT07543380Respiratory Syncytial Virus (RSV) · Japan | 3 | Completed | Pfizer | Aug 25, 2026 | 130 |
| NCT06890416Respiratory Syncytial Virus (RSV) · United States, Puerto Rico | 3 | Completed | Pfizer | Sep 30, 2025 | 526 |
| NCT06866405Respiratory Syncytial Virus Infections · United States, Argentina, South Africa and more | 3 | Recruiting | Pfizer | Feb 24, 2028 | 550 |
| NCT06593587Respiratory Tract Infections · South Korea | 3 | Completed | Pfizer | Feb 3, 2025 | 378 |
| NCT06325657Respiratory Tract Infections · South Africa | 3 | Completed | Pfizer | Jun 11, 2025 | 681 |
| NCT05900154Respiratory Tract Infections · United States | 1 | Completed | Pfizer | Feb 29, 2024 | 128 |
| NCT05886777COVID-19 · United States | 2 | Completed | Pfizer | Jan 1, 2024 | 1,142 |
| NCT05842967RESPIRATORY SYNCYTIAL VIRUS (RSV) · United States | 3 | Completed | Pfizer | Mar 18, 2024 | 885 |
| NCT05788237Influenza, Human · Argentina | 1 | Completed | Pfizer | Sep 27, 2023 | 508 |
| NCT05096208RSV · United States | 3 | Completed | Pfizer | Apr 4, 2022 | 1,028 |
| NCT05035212Lower Respiratory Tract Illness · United States, Argentina, Canada and more | 3 | Active, not recruiting | Pfizer | Jan 18, 2027 | 38,861 |
| NCT04785612Respiratory Syncytial Virus Infections · United Kingdom | 2 | Completed | Hvivo | Apr 8, 2021 | 70 |
| NCT04424316Respiratory Tract Infections · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Oct 27, 2023 | 14,727 |
How it is read
Names in the registry
- “RSVpreF”, 10 entries
- “RSVpreF Vaccine”, 2 entries
- “RSVpreF (Regimen A)”, 1 entry
- “RSVpreF (Regimen B)”, 1 entry
- “RSVpreF vaccine”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Tract Infections, 4 studies
- Respiratory Syncytial Virus Infections, 2 studies
- COVID-19, 1 study
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.